Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.